Liquidia Corporation (LQDA) - Stock Analysis
Last updated: Jun 21, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong healthcare momentum with shares up about 24% over 21 trading days and at a new closing high, supported by Q1 2026 YUTREPIA net product sales around $130M, a third straight profitable quarter, positive free cash flow, and S&P SmallCap 600 inclusion.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Liquidity Strength ⢠Cash Flow Rebound ⢠Rich Valuation LQDA posted a strong quarter with improved liquidity, positive free cash flow, and sharply better margins, but its rich valuation and legacy deficit still cap the investment case.
Price Behavior
Key Price Behavior Insights: ⢠Breakout momentum ⢠Near-high consolidation ⢠Volatility risk Support Level: $68.00-$68.70 Resistance Level: $71.50-$72.00 Over the last month, LQDA has broken out sharply and remains constructive near recent highs, but the fast run and nearby resistance suggest it may need a pause before extending higher.
Sentiment & News
Key News Insights: ⢠S&P Inclusion ⢠Conference Exposure ⢠Momentum Sentiment Liquidia is gaining positive market traction on momentum-friendly coverage, S&P SmallCap 600 inclusion, and steady conference/pipeline visibility, supporting improving investor attention.
AI Summary
LQDA has shifted from a speculative biotech to a cash-generating commercial story on YUTREPIA, but with the stock already pricing in a lot of success at roughly 211x earnings, the key takeaway is to stay bullish only if prescription growth, reimbursement access, and margins keep compounding fast enough to justify the premium.
Description
Liquidia Corporation is a U.S.-based biopharmaceutical company that develops, manufactures and commercializes therapies to address unmet clinical needs. Its portfolio includes an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension and it also markets generic treprostinil injection domestically. The company was founded in 2004 and is headquartered in Morrisville, North Carolina.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 23 | Jun 30 | LQDA | Liquidia Corporation | Strong healthcare momentum with shares up about 24% over 21 trading days and at a new closing high, supported by Q1 2026 YUTREPIA net product sales around $130M, a third straight profitable quarter, positive free cash flow, and S&P SmallCap 600 inclusion. | Active | +5.6% |
| Jun 16 | Jun 23 | LQDA | Liquidia Corporation | Constructive biotech momentum with a near-term index catalyst: Q1 2026 net product sales were about $130M, the company posted a third consecutive profitable quarter, and S&P SmallCap 600 inclusion is effective 2026-06-22. Shares are up about 20% over 21 trading days and remain above short-term trend. | Closed | +8.9% |
| Jun 8 | Jun 15 | LQDA | Liquidia Corporation | Commercial biotech momentum supported by strong YUTREPIA execution: latest quarter showed about $130M in net product sales, EPS beat consensus ($0.52 vs. $0.34), profitability improved for a third straight profitable quarter, and the stock is up about 50% over 21 trading days. | Closed | +12.4% |
| Jun 1 | Jun 8 | LQDA | Liquidia Corporation | Biotech/commercial momentum name with strong recent execution: YUTREPIA sales were about $130M-$133M, prescriptions exceeded 4,500, profitability reached a third straight quarter, adjusted EBITDA was positive, and free cash flow was strong. Stock is up about 56% over 21 trading days. | Closed | +8.8% |
| May 22 | May 29 | LQDA | Liquidia Corporation | Strong biotech execution and momentum: Q1 2026 showed about $130M of YUTREPIA net sales, more than 4,500 unique prescriptions, a third straight profitable quarter, and improved cash; stock is up about 66% over 21 trading days. | Closed | +1.4% |
| May 13 | May 20 | LQDA | Liquidia Corporation | Strong operating inflection and price momentum: Q1 2026 YUTREPIA net product sales were about $130M, with more than 4,500 unique prescriptions, a third straight profitable quarter, net income around $53M, adjusted EBITDA of $71M, and free cash flow near $50M. Shares are up about 41% over 21 trading days. | Closed | +7.3% |